Inhibition of platelet-derived growth factor receptor tyrosine kinase and downstream signaling pathways by Compound C
- Authors
- Kwon, Hyun Jin; Kim, Go-Eun; Lee, Yun Taek; Jeong, Meong-Sook; Kang, Insug; Yang, Dongki; Yeo, Eui-Ju
- Issue Date
- Apr-2013
- Publisher
- ELSEVIER SCIENCE INC
- Keywords
- AMP-activated protein kinase; Akt; Compound C; Platelet-derived growth factor receptor; Human diploid fibroblasts; Receptor tyrosine kinase
- Citation
- CELLULAR SIGNALLING, v.25, no.4, pp.883 - 897
- Journal Title
- CELLULAR SIGNALLING
- Volume
- 25
- Number
- 4
- Start Page
- 883
- End Page
- 897
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14635
- DOI
- 10.1016/j.cellsig.2012.12.016
- ISSN
- 0898-6568
- Abstract
- AMP-activated protein kinase (AMPK) has been implicated in anti-proliferative actions in a range of cell systems. Recently, it was observed that Compound C, an inhibitor of AMPK, also reduced the cell viability in human diploid fibroblasts (HDFs). Compound C-induced growth arrest was associated with a decrease in the cell cycle regulatory proteins, such as proliferating cell nuclear antigen, phosphorylated pRB, cyclin-dependent protein kinases (Cdk 2 and 4), cyclins (D and E), and the Cdk inhibitors (p21, p16, and p27). Therefore, the present study examined the molecular mechanism of the antiproliferative effects of Compound C. Although Compound C inhibited serum-induced phosphorylation of Akt and its substrate, glycogen synthase kinase-3 beta, it did not affect the Akt activity in vitro. Compound C significantly inhibited the receptor tyrosine phosphorylation and the activity of downstream signaling molecules, such as p85 phosphoinositide 3-kinase, phospholipase C-gamma 1, and extracellular signal-regulated kinase 1/2, induced by platelet-derived growth factor (PDGF) but not by epidermal growth factor- and insulin-like growth factor. In vitro growth factor receptor tyrosine kinase activity profiling revealed the IC50 for PDGF receptor-beta (PDGFR beta) to be 5.07 mu M, whereas the IC50 for the epidermal growth factor receptor and insulin-like growth factor receptor was >= 100 mu M. The inhibitory effect of Compound Con PDGFR beta and Akt was also observed in AMPK alpha(1)/alpha(2)-knockout mouse embryonic fibroblasts, indicating that its inhibitory effect is independent of the AMPK activity. The inhibitory effect of Compound Con cell proliferation and PDGFR beta tyrosine phosphorylation was also demonstrated in various PDGFR-expressing cells, including MRC-5, BEAS-2B, rat aortic vascular smooth muscle cells, and A172 glioblastoma cells. These results indicate that Compound C can be used as a potential antiproliferative agent for PDGF- or PDGFR-associated diseases, such as cancer, atherosclerosis, and fibrosis. (C) 2013 Elsevier Inc. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14635)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.